Tolifarma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 38,790 | 22,652 | 46,886 | 25,144 | 320 | 6,800 | 1,180 | - |
| Profit before tax | - | - | - | - | - | - | - | - |
| Net profit | 13,748 | 8,156 | 16,978 | 10,512 | -23,524 | -30,217 | -15,609 | -6,429 |
| Equity | 73,184 | 79,810 | 79,141 | 89,653 | 66,130 | 35,913 | 20,304 | 13,875 |
| Liabilities | 2,292 | 891 | 1,599 | 1,135 | 258 | 219 | 382 | 219 |
| Non-current assets | 25,019 | 45,424 | 47,185 | 72,532 | 41,358 | 30,009 | 9,722 | 0 |
| Current assets | 50,457 | 35,277 | 33,555 | 18,256 | 25,030 | 6,123 | 10,964 | 14,094 |
| Total assets | 75,476 | 80,701 | 80,740 | 90,788 | 66,388 | 36,132 | 20,686 | 14,094 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -33.6% | -41.6% | +107.0% | -46.4% | -98.7% | +2025.0% | -82.6% | - |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 18.2% | 10.1% | 21.0% | 11.6% | -35.4% | -83.6% | -75.5% | -45.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 18.8% | 10.2% | 21.5% | 11.7% | -35.6% | -84.1% | -76.9% | -46.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 35.4% | 36.0% | 36.2% | 41.8% | -7351.3% | -444.4% | -1322.8% | - |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 38,790 | 22,652 | 46,886 | 25,144 | 320 | 6,800 | 1,180 | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Tolifarma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-10-16 | 2024-11-07 | 4.40 |
Tolifarma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.